Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Trial Details

NCT ID
NCT05702853
Phase
PHASE1 / PHASE2
Sponsor
Medical University of South Carolina
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Cyclophosphamide injection
  • Fludarabine Injection
  • CD19-CD34t metabolically programmed CAR transduced T-cells
Locations (sample)
  • Charleston, South Carolina, United States|32.77632,-79.93275

Key Eligibility Criteria

  • Patients eligible for study participation must meet all of the following criteria:
  • Disease Related Criteria
  • Participants must have histologic confirmation of one of the following:
  • CD19+ aggressive non-Hodgkin lymphoma including any of the following subtypes

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →